Trends in Pharmacological Sciences
ReviewHistamine receptors in the CNS as targets for therapeutic intervention
Section snippets
Histamine receptors
Four metabotropic histaminergic receptors have been cloned (H1R, H2R, H3R and H4R) that are all expressed in distinctive patterns and density in the brain. H1Rs couple to Gαq/11 proteins to activate phospholipase C [7]. Other effector pathways of H1Rs include production of arachidonic acid, nitric oxide and cGMP [7]. H1Rs are found throughout the central nervous system (CNS) with particularly high densities in brain regions concerned with behavioral and nutritional state control, and their
The H3R as an attractive drug target in the brain
The pharmacological features of the H3R render it a very attractive target for the potential treatment of several CNS diseases, despite the fact that no neurological disorders have been directly ascribed to histaminergic dysfunctions. The H3R acts as an autoreceptor and also moderates the release of other neurotransmitters, including acetylcholine (ACh), dopamine, GABA, 5-hydroxytryptamine and peptides [7]. On histaminergic neuron endings, H3R activation moderates histamine synthesis and
Heterogeneous functions of histamine neurons and their therapeutic implications
The intuition that histamine might be a neurotransmitter dates back to the pioneering work of Schwartz and colleagues [26], and two independent neuroanatomical studies that unequivocally proved the existence of histaminergic neurons 27, 28. The cell bodies of histaminergic neurons are restricted to discrete cell clusters in the hypothalamic tuberomammillary nucleus (TMN) and send their axons to innervate nearly the entire CNS, with a cytoarchitecture comparable to dopaminergic, noradrenergic
Histamine and its receptors: therapeutic applications in sleep disorders
Insomnia is one of the most common disturbances of the sleep–wake cycle, whereas other pathologies such as hypersomnia and narcolepsy are less common. Insomnia is usually treated with short-lived benzodiazepines. However, the H1R is probably the most important physiological histamine target in the maintenance of waking. In animal studies, H1R agonists increase wake duration. Mice genetically deprived of the H1R (H1R-KO) exhibit a disrupted circadian rhythm and decreased activity during the
The histaminergic system and cognitive processes: therapeutic challenges
Cognitive impairments are the dreadful hallmarks of neurodegenerative and psychiatric disorders. Most treatment strategies focus on a single neurotransmitter system, even though multiple neurotransmitter systems and brain circuits are presumably involved. This is the case for the treatment of AD, in which the primary therapeutic choices are acetylcholinesterase inhibitors (AChEIs) that provide only modest and short-lived symptomatic relief [47].
A unique and remarkable feature of H3R antagonists
Histamine system and eating behavior
The interest in the histaminergic system as a potential target for the treatment of feeding disorders is driven by the unsatisfactory history of the pharmacotherapy of obesity. The drugs currently available for long-term treatment of obesity such as sibutramine, a monoamine reuptake inhibitor, and orlistat, a peripherally acting lipase inhibitor, work by different mechanisms, reflecting the complex etiology of the disease. Various combination therapies targeting disparate systems are also
Concluding remarks
The discoveries of H1R and H2R antagonists, both blockbuster drug classes for treating allergic conditions and GERD, respectively, were acknowledged with the Nobel prizes to Bovet in 1957 and Black in 1988. The discovery of the H3R by Schwartz and his group in 1983 [3] was greeted with considerable excitement, and its potential therapeutic role soon became clear as selective receptor agonists, antagonists and, more recently, inverse agonists were developed. All four histamine receptors are
References (67)
Long-term increase of hippocampal excitability by histamine and cyclic AMP
Neuropharmacology
(1997)Selective cognitive dysfunction in mice lacking histamine H1 and H2 receptors
Neurosci. Res.
(2007)Activation of peripheral and spinal histamine H(3) receptors inhibits formalin-induced inflammation and nociception, respectively
Pharmacol. Biochem. Behav.
(2007)Histamine-induced modulation of nociceptive responses
Pain
(1994)Molecular aspects of the histamine H3 receptor
Biochem. Pharmacol.
(2007)Localization of histamine H4 receptors in the central nervous system of human and rat
Brain Res.
(2009)Different role of cAMP dependent protein kinase and CaMKII in H3 receptor regulation of histamine synthesis and release
Neuroscience
(2009)Participation of histamine H3 receptors in experimental allergic rhinitis of mice
J. Pharmacol. Sci.
(2008)Evidence for the presence of a histaminergic neuron system in the rat brain: an immunohistochemical analysis
Neurosci. Lett.
(1983)Histamine in the brain: beyond sleep and memory
Biochem. Pharmacol.
(2007)
The cytoarchitecture, histochemistry and projections of the tuberomammillary nucleus in the rat
Neuroscience
Novel benzothiophene H1-antihistamines for the treatment of insomnia
Bioorg. Med. Chem. Lett.
Identification of a novel selective H1-antihistamine with optimized pharmacokinetic properties for clinical evaluation in the treatment of insomnia
Bioorg. Med. Chem. Lett.
The discovery and structure-activity relationships of 2-(piperidin-3-yl)-1H-benzimidazoles as selective, CNS penetrating H1-antihistamines for insomnia.
Bioorg. Med. Chem. Lett.
Modafinil inhibits rat midbrain dopaminergic neurons through D2-like receptors
Neuropharmacology
The brain H(3)-receptor as a novel therapeutic target for vigilance and sleep-wake disorders
Biochem. Pharmacol.
An inverse agonist of the histamine H(3) receptor improves wakefulness in narcolepsy: studies in orexin−/− mice and patients
Neurobiol. Dis.
Results of clinical trials of tiprolisant in narcolepsy and Parkinson's disease
Eur. Neuropsychopharmacol.
On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis
Exp. Neurol.
The histamine H3 receptor as a novel therapeutic target for cognitive and sleep disorders
Trends Pharmacol. Sci.
Histamine H3 receptor antagonists: from target identification to drug leads
Biochem. Pharmacol.
The hypothalamic H1 receptor: a novel therapeutic target for disrupting diurnal feeding rhythm and obesity
Trends Pharmacol. Sci.
In-vivo histamine H(3) receptor antagonism activates cellular signaling suggestive of symptomatic and disease modifying efficacy in Alzheimer's disease
Neuropharmacology
A study of the adrenotropic receptors
Am. J. Physiol.
The pharmacology of cimetidine, a new histamine H2-receptor antagonist
Br. J. Pharmacol.
Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptors
Nature
Highly-potent and selective ligands for histamine-H3 receptors
Nature
Histamine H3-receptors and sleep-wake regulation
J. Pharmacol. Exp. Ther.
Neuronal histamine and its receptors: implication of the pharmacological treatment of obesity
Curr. Med. Chem.
Histamine in the nervous system
Physiol. Rev.
Role of histamine in rodent antinociception
Br. J. Pharmacol.
Cloning and functional expression of the human histamine H3 receptor
Mol. Pharmacol.
Genomic organization and characterization of splice variants of the human histamine H3 receptor
Biochem. J.
Cited by (178)
Histamine and receptors in neuroinflammation: Their roles on neurodegenerative diseases
2024, Behavioural Brain ResearchAccumbal Histamine Signaling Engages Discrete Interneuron Microcircuits
2023, Biological PsychiatryTargeting spinal microglia with fexofenadine-loaded nanoparticles prolongs pain relief in a rat model of neuropathic pain
2022, Nanomedicine: Nanotechnology, Biology, and MedicineHistamine H<inf>3</inf> Receptor Function Biases Excitatory Gain in the Nucleus Accumbens
2021, Biological PsychiatryThe tuberomamillary nucleus in neuropsychiatric disorders
2021, Handbook of Clinical NeurologyCitation Excerpt :Interestingly, no changes were found in HDC-mRNA expression in the TMN compared with controls (Shan et al., 2012b), which is in agreement with the finding in a large cohort of AD patients where only slightly lower levels of lumbar CSF t-MeHA were found compared with controls (Motawaj et al., 2010), and suggest that histamine production was largely compensated for by the remaining TMN neurons. As they were found to stimulate the release of various neurotransmitters, including histamine and acetylcholine in the rat cortex, H3R antagonists/inverse agonists were proposed as potential treatment for AD (Passani and Blandina, 2011). However, the collective data show that the histaminergic system is relatively unaffected in AD patients, in line with a lack of improvement in cognition in patients with AD in several randomized controlled trials of H3R antagonists/inverse agonists (Egan et al., 2012; Grove et al., 2014; Kubo et al., 2015).